Ombrabulin Plus Cisplatin Not Effective for Advanced Soft-Tissue Sarcomas

Share this content:
Combination ombrabulin and cisplatin improved progression-free survival, but did not demonstrate sufficient clinical benefit in soft-tissue sarcomas.
Combination ombrabulin and cisplatin improved progression-free survival, but did not demonstrate sufficient clinical benefit in soft-tissue sarcomas.

The combination of ombrabulin and cisplatin significantly improved progression-free survival, but did not demonstrate a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its therapeutic use, a new study published online early in the journal The Lancet Oncology has shown.

For this international, double-blind, placebo-controlled phase III trial, researchers sough to assess the efficacy and safety of ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas who had previously received treatment with an anthracycline and ifosfamide.

Researchers enrolled 355 patients and randomly assigned them to receive cisplatin 75mg/m2 IV plus either ombrabulin 25mg/m2 IV or placebo every 3 weeks.

Results showed that median progression-free survival was 1.54 months (95% CI: 1.45-2.69) in the ombrabulin group compared with 1.41 months (95% CI: 1.38-1.58) in the placebo group (HR = 0.76; 95% CI: 0.59-0.98; P = 0.0302).

In regard to safety, grade 3-4 neutropenia and thrombocytopenia were more common the ombrabulin group. A total of 18 patients in the ombrabulin group died as a result of adverse events versus 10 patients in the placebo group.

Reference

  1. Blay J-Y, Papai Z, Tolcher AW, et al. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015. [Epub ahead of print]. doi: 10.1016/S1470-2045(15)70102-6.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters